QuidelOrtho (QDEL)

• Market cap: $1.66B
• 1 day: -2.42%
• 5 days: -10.89%
• 1 month: -31.64%
• 3 months: -43.82%
• 6 months: -38.35%
• Year to date: -45.47%
• 1 year: -37.15%
• 5 years: -78.25%
• 10 years: 6.04%
• Sector: Healthcare
• Industry: Medical Devices

About: QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.

Employees: 6,600

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

56% more repeat investments, than reductions

Existing positions increased: 111 | Existing positions reduced: 71

33% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 42

5% more funds holding

Funds holding: 259 [Q3] → 271 (+12) [Q4]

2.95% more ownership

Funds ownership: 106.0% [Q3] → 108.95% (+2.95%) [Q4]

8% more call options, than puts

Call options by funds: $13.9M | Put options by funds: $12.9M

1% more capital invested

Capital invested by funds: $3.25B [Q3] → $3.26B (+$17M) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 9 [Q3] → 6 (-3) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $25 2% upside
• Avg. target: $44 78% upside
• High target: $61 148% upside

3 analyst ratings

• positive: 1 33%
• neutral: 1 33%
• negative: 1 33%

JP Morgan Casey Woodring 0% 1-year accuracy 0 / 7 met price target	2% upside $25	Underweight Maintained	21 Apr 2025
RBC Capital Conor McNamara 5% 1-year accuracy 2 / 37 met price target	148% upside $61	Outperform Maintained	13 Feb 2025
UBS John Sourbeer 0% 1-year accuracy 0 / 3 met price target	83% upside $45	Neutral Maintained	13 Feb 2025